196 related articles for article (PubMed ID: 32864984)
1. Low-Molecular-Weight Heparin and Fondaparinux Use in Pediatric Patients With Obesity.
Garner MP; Onuoha CP; Fenn NE
Ann Pharmacother; 2021 May; 55(5):666-676. PubMed ID: 32864984
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
3. Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis.
Kumar A; Talwar A; Farley JF; Muzumdar J; Schommer JC; Balkrishnan R; Wu W
J Am Heart Assoc; 2019 May; 8(10):e012184. PubMed ID: 31070069
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Effects of Low-Molecular-Weight Heparin and Fondaparinux on Liver Function in Patients With Pulmonary Embolism.
Yang X; Li N; Guo T; Guan X; Tan J; Gao X; Wu Y; Jia L; Gu M; Hua L; Liu H
J Clin Pharmacol; 2020 Dec; 60(12):1671-1678. PubMed ID: 32639644
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of low-dose parenteral anticoagulation, incidence of major bleeding and mortality: a multi-centre cohort study using the French national health data system.
Bouget J; Balusson F; Kerbrat S; Roy PM; Viglino D; Lacut K; Pavageau L; Oger E
Eur J Clin Pharmacol; 2022 Jul; 78(7):1137-1144. PubMed ID: 35385975
[TBL] [Abstract][Full Text] [Related]
7. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Lim W; Dentali F; Eikelboom JW; Crowther MA
Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285
[TBL] [Abstract][Full Text] [Related]
12. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360
[TBL] [Abstract][Full Text] [Related]
15. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Thachil J
Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
[TBL] [Abstract][Full Text] [Related]
16. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
O'Brien SH; Kulkarni R; Wallace A; Hamblin F; Burr S; Goldenberg NA
J Thromb Haemost; 2014 Nov; 12(11):1822-5. PubMed ID: 25182454
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108
[TBL] [Abstract][Full Text] [Related]
18. The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
Prandoni P; Cattelan AM; Carrozzi L; Leone L; Filippi L; De Gaudenzi E; Villalta S; Pesavento R;
Thromb Res; 2020 Dec; 196():395-397. PubMed ID: 33007739
[No Abstract] [Full Text] [Related]
19. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Martineau P; Tawil N
Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
